Evidence map›Paper›PMID 38722231›Full record

ReviewFuture medicinal chemistry2024

Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022).

Chloé Rémondin, Serge Mignani, Christophe Rochais, Patrick Dallemagne

Abstract readReview
In one paragraph

Review in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chloé RémondinNormandie Univ., UNICAEN, CERMN, 14000, Caen, France.ORCID 0000-0002-7256-9154
Serge MignaniNormandie Univ., UNICAEN, CERMN, 14000, Caen, France.ORCID 0000-0002-1383-5256
Christophe RochaisNormandie Univ., UNICAEN, CERMN, 14000, Caen, France.ORCID 0000-0001-7996-2082
Patrick DallemagneNormandie Univ., UNICAEN, CERMN, 14000, Caen, France.ORCID 0000-0002-4845-615X

Funding

French Fondation pour la Recherche Médicale ALZ2019120096273
6 · The paper itself

Abstract

β-Phenylalanine derivatives (β-PAD) represent a structural family of therapeutic interest, either as components of drugs or as starting materials for access to key compounds. As scaffolds for medicinal chemistry work, β-PAD offer the advantage of great diversity and modularity, a chiral pseudopeptidic character that opens up the capacity to be recognized by natural systems, and greater stability than natural α-amino acids. Nevertheless, their synthesis remains a challenge in drug discovery and numerous methods have been devoted to their preparation. This review is an update of the access routes to β-PAD and their various therapeutic applications.

Indexed as

Chemistry, PharmaceuticalPhenylalanineDrug DiscoveryHumansMolecular StructurePhenylalanineaminoarylpropionic acidsbiocatalysisenantioselectivitypseudopeptidesβ-aminoacidsβ-phenylalanine

Identifiers

PMID38722231
PMCPMC11221601

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.